Your session is about to expire
← Back to Search
Radioimmunotherapy + Stem Cell Transplant for Leukemia and Myelodysplastic Syndrome
Study Summary
This trial is studying the side effects and best dose of a radioactive agent linked to an antibody when given with a donor stem cell transplant to treat patients with high-risk leukemia or myelodysplastic syndrome.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung function is severely reduced or I need extra oxygen.I had a specific type of stem cell transplant and meet certain conditions.I can take care of myself and perform daily activities without help.I am currently pregnant or breastfeeding.My tissue type matches the recipient's requirements.I do not have any infections that aren't responding to treatment.I have had a bone marrow transplant from a donor.I am allergic to certain mouse-derived cancer drugs.I cannot undergo radiotherapy due to health reasons.I have been diagnosed with AML, ALL, high-risk MDS, or MPAL.I have liver issues such as cirrhosis or alcoholic hepatitis.I am between 18 and 75 years old.My liver iron concentration is below 7 mg/g, confirmed by MRI.My leukemia has spread to my brain or spinal cord.I do not have heart disease symptoms or take specific heart medications.I have consulted a gastroenterologist before my transplant.I do not have a specific type of compatible donor for a transplant.I am able to understand and give informed consent.I am fertile and not willing to use birth control.
- Group 1: Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any specific requirements for people who want to join this clinical trial?
"This study is only for myeloid leukemia patients aged 18-75. Around 30 people will be accepted in total."
Does this study require all participants to be over the age of 60?
"Eligibility criteria for this trial include being between 18-75 years old."
How many volunteers are being sought for this experiment?
"The clinical trial is currently ongoing and recruiting patients, as reflected on the website clinicaltrials.gov. This study was posted on 7/10/2019, with the most recent update taking place on 10/24/2022. They are looking for 30 individuals total from 1 location."
What types of diseases or conditions is Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 usually prescribed for?
"The application of Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 can be used to treat leukemia, infection, and bone marrow transplant patients."
Are there any patients participating in this clinical trial at the moment?
"That is correct, the online information regarding this clinical trial indicates that it is still recruiting patients. This study was first posted on 7/10/2019 and edited for the last time on 10/24/2022. Currently, 30 people are needed to participate at 1 location."
Are there similar ongoing or completed studies that involve the use of Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10?
"There are a total of 1110 ongoing studies related to the efficacy of Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10. Of these, 202 have progressed to phase 3 clinical trials. Additionally, although many of the Philadelphia based trials are for this treatment, there are 31166 locations running similar investigations."
Share this study with friends
Copy Link
Messenger